Poor Antibody Response After Two Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in Transplant Recipients
Alessandra Mazzola, Ève Todesco, Sarah Drouin, Fanny Hazan, Stéphane Marot, Dominique Thabut, Shaïda Varnous, Cathia Soulié, Benoı̂t Barrou, Anne‐Geneviève Marcelin, Filomena Conti
Abstract
A low anti-spike antibody response of 28.6% was observed 28 days after BNT162b2 vaccine second dose among 133 solid organ transplant recipients without previous coronavirus disease 2019 (COVID-19). No serious adverse events were recorded. Four severe COVID-19 cases were reported between or after the 2 doses. Our data suggest to change the vaccine strategy.
Topics & Concepts
MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakAdverse effectCoronavirusAntibody responseAntibodyImmunologyVirologySevere acute respiratory syndrome coronavirusRespiratory systemBetacoronavirusInternal medicineDiseaseInfectious disease (medical specialty)OutbreakSARS-CoV-2 and COVID-19 ResearchHeparin-Induced Thrombocytopenia and ThrombosisAnimal Virus Infections Studies